Global Antibacterial drug Market Expected to Reach XX Million by 2025
According to a new report published by Reports Monitor titled, “Antibacterial Drug market by drug class, by route of administration, and by end user: Global Opportunity Analysis and Industry Forecast, 2017–2025,” the antibacterial drug market was valued at XX million in 2016, and is projected to reach at XX million by 2025, growing at a CAGR of XX% from 2017 to 2025. North America dominates the antibacterial drug market, in terms of value, and is expected to maintain this trend throughout the forecast period.
Development of novel drug with improves efficacy, fewer side effect and reduce time for action are anticipated to offer good opportunity for growth of the antibacterial drug market.
Rising incidence of infectious and other diseases and growing government support in research and development activity of antibiotics are some of the major factors driving the growth of the market. Growing number of antibiotic resistance population is major restrains to this market but it can be converted into opportunity by developing new drug with broader spectrum.
Recent Research into efficacy and action of the therapies led to some innovative formulation, this can increase the demand of this market. Proved multidrug therapies in case of antibiotic resistance are opens untapped market and able to generates more prescription by the doctors. Low return on investment and expiry of patented drugs are two major challenges faced by this market. Unregulated, incomplete or over prescription of antibacterial drugs has resulted into increased antibiotic resistance towards conventional antibiotics this can be the restraining factor to the market.
KEY FINDINGS • Beta-lactums of drug class segment has a largest market share in antibacterial drugs market. • In route of administration segment oral route holds higher market share as availability of different formulation can achieved patient compliance. • Clinics segment is contributing higher share in the antibacterial drugs market. • North America dominates the antibiotic drugs market due to increased in number of infectious patient population. • Asia-Pacific is expected to grow at higher rate due to rising patient population and developing healthcare infrastructure in that region.
The major companies profiled in the report include Pfizer, Inc., Merck & Co., Inc. , GlaxoSmithKline plc., Novartis AG, Eli Lilly and Company, Johnson & Johnson, Sanofi, AstraZeneca plc and Bayer AG.
We at Garner Insights.com provide a comprehensive analysis by providing in-depth reports of the various market verticals. Our Mission is to provide a detailed analysis of the vast markets worldwide backed by rich data. Decision makers can now rely on our well-defined data gathering methods to get the correct and accurate market forecasting along with detailed analysis.